Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population

Abstract

These findings suggest that measuring serum HE4 concentrations along with CA125 concentrations may provide higher accuracy for detecting ovarian cancer.

Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses

“…There may be several explanations for the heterogeneity observed among previous studies, and in our opinion, the most intriguing are the differences in the study design, study population, demographic characteristics of patients, ovarian cancer prevalence, sample size, control group (healthy women or women with benign diseases), methods of measuring serum CA125 or HE4 levels (ELISA or chemiluminescent microparticle immunoassay) and cutoff values of CA125/HE4 assays (manufacturer or clinical practice). Furthermore, several studies did not take into account the effect of the uneven distribution of patients in pre-and post-menopausal status, histological subtypes and FIGO stages when interpreting the results of CA125 and HE4 measurements (Moore et al, 2009;Moore et al, 2010;Kim et al, 2011;Montagnana et al, 2011;Ruggeri et al, 2011;Van Gorp et al, 2011). Overall, each of these points theoretically represent a source of heterogeneity among studies likely influencing the markers' diagnostic performances.…”

Serum-based protein biomarkers for detection of lung cancer

“…Presently only a few blood biomarkers have proven useful for diagnosis of primary cancers. These include serum PSA for prostate cancer; bladder tumor antigen (BTA) and nuclear matrix protein-22 for bladder cancer [65,66]; alpha-fetoprotein (AFP) for hepatocellular carcinoma and testicular cancers; catecholamines for neuroblastoma; immunoglobulins for multiple myeloma; [67] and human epididymis protein 4 (HE4) for ovarian cancer [68]. These are currently approved by FDA but are not sensitive enough for screening and early detection in selected populations.…”

Efektivitas HE4 sebagai Metode Skrining Terbaru untuk Diagnosis Dini Kanker Ovarium

“…Tabel. 4.3 Serum HE4 dan CA125 pada setiap bagian dari populasi yang diteliti 11 Dari hasil penelitian ini di dapatkan bahwa sensitifitas HE4 dalam mengidentifikasi kanker ovarium pada wanita dengan massa adneksa sebesar 73,1% dengan spesifisitas 95% dan sensitifitas 71,8% pada spesifisitas 98%. Penelitian ini juga mendukung bahwa serum HE4 lebih baik dalam membedakan antara kanker ovarium dan tumor jinak.…”